Eisai files first marketing application for lenvatinib in Japan

26 June 2014

Japanese pharma major Eisai (TYO: 4523) said today that it has submitted its first marketing authorization application for its novel in-house developed anticancer agent lenvatinib mesylate for the treatment of thyroid cancer in Japan.

This application for Japan marks the first submission for lenvatinib in the world following the completion of a global clinical trial, the company noted. If approved, lenvatinib will be the first molecular-targeted small molecule agent developed by a Japanese pharmaceutical company. Eisai has previously said it believes this drug could generate sales of 30 billion yen ($294 million) by fiscal 2020.

Clinical backing

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK